The proven lifeline for older hearts
A comprehensive meta-analysis of 34 studies spanning three decades provides the strongest evidence to date that guideline-directed medical therapy (GDMT) significantly improves survival in older patients (≥65 years) with heart failure and reduced ejection fraction. The analysis, involving over 92,000 patients, found GDMT was associated with a 31% reduction in the risk of all-cause mortality. While acknowledging high statistical heterogeneity, the authors highlight that this evidence addresses a critical gap and offers clinically relevant insights for contemporary practice in an aging population.
Why it might matter to you:
This meta-analysis directly informs evidence-based decision-making for a large and growing patient demographic you will frequently encounter. It reinforces the substantial survival benefit of established therapies in a group sometimes underrepresented in trials, providing a solid foundation for clinical recommendations. Understanding this evidence can help guide discussions about treatment goals and adherence with older patients.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
